Suche

Koselugo

selumetinib sulfate · L01EE04

Phakomatosen ohne Klassifikation Differenzialdiagnostik und Therapie‑Standard im Kindesalter

Phakomatosen umfassen eine heterogene Gruppe neurokutaner Erkrankungen, die durch Fehlentwicklungen von Haut, Nervensystem und oft weiteren Organen gekennzeichnet sind. Die Neurofibromatose Typ 1 (NF‑1) ist das am häufigsten vorkommende …

Koselugo · 4.5 · 28 In vitro, selumetinib is an inhibitor of OAT3. The potential for a clinically relevant effect on the pharma

Koselugo · 4.5 · Active substances that may decrease selumetinib plasma concentrations Co-administration with a strong CYP3A4 i

Koselugo · 4.5 · Active substances that may decrease selumetinib plasma concentrations Co-administration with a strong CYP3A4 i

Koselugo · 4.5 · Active substances that may increase selumetinib plasma concentrations Co-administration with a strong CYP3A4 i

Koselugo · 4.5 · Active substances that may increase selumetinib plasma concentrations Co-administration with a strong CYP3A4 i

Koselugo · 4.5 · Active substances whose plasma concentrations may be altered by selumetinib

Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis

pubmed · 38502338